Power Law company profile

Alnylam Pharmaceuticals

Biotech & Life Sciences · Cambridge, United States · Founded 2002 · IPO 2004 Decacorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$39B

Market cap · Apr/2026

Revenue

$2.99B

Latest reported FY

Investors

9 investors on Alnylam Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 2 investors entered at this stage

Merck & Co.

Abingworth

Series B+ 7 investors entered at this stage

ARCH Venture Partners

Max Planck Society

Massachusetts Institute of Technology

Max Planck Innovation

Cardinal Partners

Polaris Partners

Atlas Venture

Global footprint

Where Alnylam Pharmaceuticals has talent and traffic

AI talent share

0.4% of workforce is AI talent
(12 of 2,822 staff)

Core AI30.11%

Other AI90.32%

Non-AI workforce2,81099.57%

Web traffic by country

80K monthly visits
across markets

🇺🇸 United States58.5%

🇬🇧 United Kingdom9%

🇨🇦 Canada4.4%

🇮🇳 India4.1%

🏳️ Korea3.6%

Top 5 markets shown

Patent intelligence

$573M patent portfolio · 448 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with topic prominence vs same-sector peers.

Estimated portfolio value

$573M

1.5% of market cap · 3.5× smaller than top peer Ablynx ($2B)

448 active patent families

Where Alnylam Pharmaceuticals innovates Molecular biologyDiseaseDouble strandCell biologyGene expression

Tech-focus vs peers

Where Alnylam Pharmaceuticals concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Alnylam Pharmaceuticals and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Alnylam Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo